China's speed! The new crown vaccine is available for mass production.

On August 9, pharmaceutical giant AstraZeneta Pharmaceuticals entered into a licensing agreement with China's Shenzhen-based Kantai Biological Products Co., Ltd., which will have exclusive clinical research and development, production and commercialization interests in the Vaccine in the Chinese market, The Reference News reported.
this means that Chinese companies are licensed to produce the Oxford Vaccine, which currently includes five of the six vaccines in Phase III clinical trials in the Chinese market.
reported that the vaccine, developed by AstraZeneta in cooperation with the Jenner Institute at Oxford University in the United Kingdom, had achieved encouraging results in early trials, with volunteers developing strong immune responses and not feeling serious adverse reactions.
August 7, according to the Communist Youth League Central Committee of the official micro-news, the National Pharmaceutical Group of China Bio recently disclosed that the Beijing Institute of Biological Products new crown inactivated vaccine production workshop has passed the state-related departments organized by the joint biosecurity inspection, with the conditions for use.
, the production facility has just obtained a new crown vaccine production license.
beijing's high-grade bioseedic production facility, which has passed inspections, is the world's first and largest production plant for new crown inactivated vaccines.
beijing Institute of Biological Products in just two months, on April 15 completed the construction of the workshop, creating a new crown inactivated vaccine workshop construction of the "Fire Mountain" speed.
mid-July, experts from relevant state departments conducted a comprehensive inspection of biosecurity in the production workshop of the new crown vaccine of the Beijing Institute of Biological Products, and concluded that the production workshop basically met the requirements of the relevant national standards and could be put into large-scale production of the new crown vaccine. About 165 vaccines are currently in trial, 26 are in clinical trials and six are in Phase III clinical trials, three of them from China, and it is incredible to see such results in the short term, said Michael Ryan, WHO's head of the Health Emergency Program, which will have a capacity of 220 million doses in
. according to
, China National Pharmaceutical Group China Bio in Beijing and Wuhan, two biological products research institutes have built a high-grade biosecurity production facilities, the two research institutes of the production workshop put into use, China Bio will be able to ensure that the new crown vaccine annual production capacity of a total of 220 million doses.
At present, China has a number of teams including the chinese pharmaceutical group Yang Xiaoming, the leading group of scientific research, military academy of military medicine, Chen Wei academician team, including the new crown vaccine into the clinical trial stage, becoming the world's most effective research and development of the new coronavirus vaccine.
Pharmaceutical Group China Bio-responsible research and development of inactivated vaccine has now entered the clinical phase III trial stage, and has a large-scale mass production capacity, all the progress is in the global leading position.
yang Xiaoming, chairman of China Biotechnology Co., Ltd., a Pharmaceutical Group, said in an exclusive interview with reporters that he was optimistic that the domestic new coronavirus inactivated vaccine would be available as soon as possible by the end of this year or early next year.
netizens hot discussion: put up their sleeves, and so on lined up to fight the vaccine new crown inactivated vaccine production workshop was completed, to fill the gap in the domestic hardware infrastructure.
At the same time, with the relevant departments to prepare the "first vaccine biosecurity facility standards and biosecurity system documents", to fill the gaps in China's human vaccine high-grade biosecurity workshop hardware standards and management system.
the construction and use of this workshop provides a safe and reliable hardware guarantee for the current mass production of vaccines and for ensuring the efficiency and production capacity of vaccine research and development in the event of a possible future outbreak of major infectious diseases.
netizens hot discussion: look forward to, look forward to, look forward to!